Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus TARACTAN.
HALOPERIDOL INTENSOL vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has moderate affinity for alpha-1 adrenergic receptors and low affinity for H1 histamine and muscarinic cholinergic receptors.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Oral (Intensol): 0.5-5 mg twice or three times daily. Maximum: 100 mg/day.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14-37 hours (average 21 hours) after oral administration; may be longer in elderly or hepatic impairment.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Primarily hepatic metabolism with renal elimination of metabolites; about 40% excreted in urine and 15% in feces via bile.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic